Maryland 2026 Session Status: Introduced 11 D cosponsors

HB0484 — Corporate Income Tax - Addition Modification - Direct-to-Consumer Pharmaceutical Advertising

Last action — Hearing (Primary, House of Origin)

  1. 1
    Introduced
  2. 2
    In Committee
  3. 3
    Passed House of Delegates
  4. 4
    Passed Senate
  5. 5
    To Executive
  6. 6
    Enacted

This bill has been introduced in the House of Delegates. Introduced January 23, 2026. It must pass committee before a floor vote.

Next likely step: a committee referral and hearing.

Odds of enactment

Low chance

Based on the sponsor, cosponsors, and committee posture, this bill has a low chance of becoming law.

Upgrade to see the exact probability and what's driving it.

A statistical estimate from our own model of past outcomes — an insight, not a guarantee. Policymaking is volatile.

Prognosis

Not enough signal yet

Not enough signal yet to read this bill's trajectory — we surface a likelihood only once there's real movement (stage, sponsorship, committee, or votes) to point to.

Based on stage, sponsorship breadth, committee status, recorded votes, and cross-state momentum — a description of the observable signals, not a prediction.

Summary

Providing an addition modification under the corporate income tax for the amount of certain direct-to-consumer advertising expenses for certain covered drugs paid or incurred during the taxable year that are deducted under the Internal Revenue Code; and applying the Act to all taxable years beginning after December 31, 2025.

Bill Text

We don't have the full text on file for this bill yet.

Read HB0484 on the official Maryland source →

Action History

  1. Hearing (Primary, House of Origin)

  2. First Reading (House of Origin)

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 10 co-sponsors · 177 not signed on

Sponsors (1)

Co-sponsors (10)

Not signed on (177)

177 members have not signed on to this bill.

Show all 177 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

taxation healthcare technology
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does HB0484 do?
Providing an addition modification under the corporate income tax for the amount of certain direct-to-consumer advertising expenses for certain covered drugs paid or incurred during the taxable year that are deducted under the Internal Revenue Code; and applying the Act to all taxable years beginning after December 31, 2025.
Who sponsors HB0484?
HB0484 is sponsored by Delegate Natalie Ziegler (Democrat), Delegate Jessica Feldmark (Democrat), Delegate Jen Terrasa (Democrat), Delegate Jackie Addison (Democrat), Delegate Lorig Charkoudian (Democrat), Delegate Bonnie Cullison (Democrat), Delegate Eric Ebersole (Democrat), Delegate Pam Lanman Guzzone (Democrat), Delegate Terri L. Hill (Democrat), Delegate Gabriel M. Moreno (Democrat), and Delegate Courtney Watson (Democrat).
What is the current status of HB0484?
This bill has been introduced in the House of Delegates. Introduced January 23, 2026. It must pass committee before a floor vote.
Where can I track HB0484?
Track HB0484 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on HB0484

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of HB0484

Last checked for changes about 3 hours ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →